CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 147 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2023. The put-call ratio across all filers is 0.86 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,151,134 | -37.3% | 41,829 | -22.7% | 0.00% | -100.0% |
| Q2 2023 | $1,835,647 | +51.9% | 54,101 | +61.1% | 0.00% | – |
| Q1 2023 | $1,208,388 | +2489.6% | 33,585 | +3107.7% | 0.00% | – |
| Q4 2022 | $46,664 | -36.1% | 1,047 | -59.2% | 0.00% | – |
| Q3 2022 | $73,000 | -2.7% | 2,564 | -8.7% | 0.00% | – |
| Q2 2022 | $75,000 | -93.3% | 2,808 | -91.4% | 0.00% | – |
| Q1 2022 | $1,118,000 | -38.1% | 32,831 | -29.7% | 0.00% | – |
| Q4 2021 | $1,806,000 | +65.8% | 46,712 | +131.4% | 0.00% | – |
| Q3 2021 | $1,089,000 | +21680.0% | 20,185 | +13447.0% | 0.00% | – |
| Q2 2021 | $5,000 | +66.7% | 149 | -11.8% | 0.00% | – |
| Q1 2021 | $3,000 | -99.7% | 169 | -99.7% | 0.00% | – |
| Q4 2020 | $866,000 | +14333.3% | 49,497 | +12857.3% | 0.00% | – |
| Q3 2020 | $6,000 | +100.0% | 382 | +52.2% | 0.00% | – |
| Q2 2020 | $3,000 | – | 251 | -23.9% | 0.00% | – |
| Q1 2020 | $0 | – | 330 | +8.2% | 0.00% | – |
| Q4 2019 | $0 | – | 305 | +35.6% | 0.00% | – |
| Q3 2019 | $0 | -100.0% | 225 | -60.7% | 0.00% | – |
| Q2 2019 | $1,000 | -50.0% | 573 | +19.1% | 0.00% | – |
| Q1 2019 | $2,000 | – | 481 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,200,000 | $88,064,000 | 14.40% |
| Octagon Capital Advisors LP | 759,898 | $20,912,393 | 3.21% |
| TSP Capital Management Group, LLC | 251,695 | $6,926,645 | 2.67% |
| 5AM Venture Management, LLC | 310,270 | $8,538,630 | 2.46% |
| COMMODORE CAPITAL LP | 706,665 | $19,447,421 | 2.27% |
| ACUTA CAPITAL PARTNERS, LLC | 122,341 | $3,366,824 | 2.26% |
| Redmile Group, LLC | 1,635,938 | $45,021,014 | 2.14% |
| RTW INVESTMENTS, LP | 3,463,201 | $95,307,292 | 2.01% |
| Eversept Partners, LP | 588,143 | $16,185,695 | 1.37% |
| Affinity Asset Advisors, LLC | 150,000 | $4,128,000 | 1.16% |